Genmab

  • Genmab raised new capital to fund the further development of in-house drug candidate HuMax-Tissue Factor-ADC and other programs
  • Kempen & Co was engaged as Joint Lead Manager and supported the company in one of the largest European Life Sciences ECM transactions of the past year